(AUTL) –
-
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
-
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
-
Autolus Therapeutics plc (AUTL) PT Raised to $11 at Truist Securities
-
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractor
-
Form 8-K Autolus Therapeutics For: Mar 26
-
Autolus Therapeutics (AUTL) Announces Board Changes
-
Autolus Therapeutics Announces Changes to its Board of Directors
-
Autolus Therapeutics (AUTL) Announces 33.33M Share Offering by Selling Stockholders
-
Form S-3ASR Autolus Therapeutics
-
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
-
Form SC 13D/A Autolus Therapeutics Filed by: Kellnerova Renata
-
Form 10-K Autolus Therapeutics For: Dec 31
-
Form 8-K Autolus Therapeutics For: Mar 21
-
Autolus Therapeutics plc (AUTL) PT Raised to $10 at Truist Securities
-
Form 8-K/A Autolus Therapeutics For: Mar 14
-
Autolus Therapeutics plc (AUTL) PT Raised to $10 at Truist Securities
-
Form 8-K Autolus Therapeutics For: Mar 14
-
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
-
Autolus Therapeutics (AUTL) Receives MHRA Certification for Nucleus Manufacturing Site
-
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
-
Autolus Therapeutics (AUTL) announces publication in Blood Cancer Journal
-
Autolus Therapeutics announces publication in Blood Cancer Journal
-
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
-
Bob Azelby to join Cardinal Health Board of Directors
-
Form D Autolus Therapeutics
-
Autolus Therapeutics announces publication in Nature CommunicationsÂ
-
Form SC 13D Autolus Therapeutics Filed by: BioNTech SE
-
Form SC 13G/A Autolus Therapeutics Filed by: Paradigm Biocapital Advisors LP
-
Form SC 13G/A Autolus Therapeutics Filed by: ARMISTICE CAPITAL, LLC
-
Form SC 13G/A Autolus Therapeutics Filed by: Deep Track Capital, LP
-
Form SC 13G/A Autolus Therapeutics Filed by: Syncona Portfolio Ltd
-
Form 8-K Autolus Therapeutics For: Feb 13
-
Autolus Therapeutics plc (AUTL) PT Raised to $9 at Needham & Company
-
Form 424B5 Autolus Therapeutics
-
Form 8-K Autolus Therapeutics For: Feb 08
-
Autolus Therapeutics (AUTL) Prices 58.33M Share Offering at $6/sh
-
Autolus Announces Pricing of Underwritten Offering
-
Autolus Therapeutics (AUTL) Enters License and Option Agreement with BioNTech SE (BNTX)
-
Autolus Therapeutics (AUTL) Files Mixed Shelf
-
Form 8-K Autolus Therapeutics For: Feb 06
-
Form S-3ASR Autolus Therapeutics
-
Form SC 13G/A Autolus Therapeutics Filed by: Tetragon Financial Management LP
-
Form 8-K Autolus Therapeutics For: Jan 22
-
Autolus Therapeutics (AUTL) announces publication in ACS Chemical Biology
-
Autolus Therapeutics announces publication in ACS Chemical Biology
-
Autolus Therapeutics (AUTL) announces acceptance of BLA for obecabtagene autoleucel as potential treatment for r/r Adult B-cell ALL
-
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leuke
-
Form 8-K Autolus Therapeutics For: Jan 09
-
Autolus Therapeutics (AUTL) Appoints Robert W. Azelby to its Board
-
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
Back to AUTL Stock Lookup
